Glenmark Pharma Reports Q4 Net Profit Surge to ₹301 Crore; Proposes 250% Dividend
Glenmark Pharmaceuticals Ltd announced a dramatic increase in consolidated net profit to ₹301.4 crore for Q4 on Friday (May 29), fueled by…
Torrent Pharma Q4 Net Profit Plummets Despite Revenue Surge; Announces ₹9 Dividend
Torrent Pharmaceuticals Ltd announced on Friday (May 22) a consolidated net profit decrease of 21.9% year-on-year, reaching ₹389 crore for the…
Sun Pharma is close to finalizing a $12 billion agreement with Organon; announcement expected shortly, say sources.
Sun Pharmaceutical Industries Ltd. is nearing the completion of a deal to acquire assets from Organon, with an announcement anticipated…
Aurobindo Pharma Set to Initiate ₹800 Crore Buyback at ₹1,475 Per Share Starting April 23
Aurobindo Pharma Ltd announced on Tuesday (April 21) that it has filed the Letter of Offer for its equity share buyback worth up to ₹800 crore…
OneSource Specialty Pharma obtains EU-GMP renewal for its Bengaluru Unit II facility.
OneSource Specialty Pharma Ltd announced on Friday (April 17) that it has successfully renewed its European Union Good Manufacturing Practices…
AstraZeneca Pharma Secures CDSCO Approval to Import Calquence 100 mg Tablets for Leukaemia Treatment
Pharmaceutical company AstraZeneca Pharma India Ltd announced on Friday (April 10) that it has obtained approval from the Central Drugs…
Sun Pharma appoints Kirti Ganorkar as Managing Director; Dilip Shanghvi to remain as Executive Chairman.
Pharmaceutical company, Sun Pharmaceutical Industries Ltd, announced on Friday (June 13) the appointment of Kirti Ganorkar as its new managing…
Orbimed to sell 2.27% ownership in Marksans Pharma through a ₹256.8 crore block transaction.
Global healthcare investment firm, OrbiMed Asia IV Mauritius FVCI Ltd, announced on Tuesday (June 10) a block trade to divest 2.27% of its…
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
AI-Powered Drug Development Pipeline Highlights: LP-300 Lantern’s Phase 2 HARMONIC™ trial for LP-300 continued to advance during Q1 2025 with…